Results 231 to 240 of about 8,230,812 (271)

Plasma Extracellular Vesicle Serpin G1 and CD14 Levels are Associated with Major Adverse Cardiovascular Events and Major Adverse Limb Events in Patients Undergoing Femoral Endarterectomy

European Journal of Vascular and Endovascular Surgery, 2023
Plasma extracellular vesicles (EV) are an emerging source of biomarkers for diagnosis and prognosis of cardiovascular disease (CVD). Risk stratification for common adverse events such as major adverse limb events (MALE) and major adverse cardiovascular events (MACE) by an EV blood sample could improve healthcare management by individualising drug ...
Gerard Pasterkamp, Nathalie Timmerman, Gert Jan de Borst   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Elevated Lipoprotein(a) levels increase Major Adverse Limb Event

European Heart Journal, 2022
Abstract Background High lipoprotein(a) levels are involved in the development of cardiovascular events, as particularly in myocardial infarction, stroke, and peripheral artery disease. Studies assessing prognostic values of lipoprotein(a) levels on the lower limbs are lacking.
Guédon, Alexis, Freminville, Jean-Baptiste, Mirault, Tristan, Mohamedi, Nassim, Rance, Bastien, Fournier, Natalie, Paul, Jean-Louis, Messas, Emmanuel, Goudot, Guillaume   +8 more
openaire   +2 more sources

Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events

Journal of the American College of Cardiology, 2023
Abstract Background Lipoprotein(a) lowering therapy to reduce atherosclerotic cardiovascular disease is currently under investigation in clinical trials, but lipoprotein(a) may also be implicated in peripheral arterial disease (PAD), abdominal aortic aneurysms (AAA), and major adverse limb events ...
Peter E Thomas, Signe Vedel-Krogh, Børge G. Nordestgaard   +2 more
exaly   +4 more sources

Chronic Kidney Disease Predicts Adverse Major Cardiovascular Events and Adverse Limb Events in Patients With Diabetes and Peripheral Arterial Disease

The International Journal of Lower Extremity Wounds, 2023
This study aims to explore the effect in each stage of chronic kidney disease (CKD) on the major adverse cardiovascular events (MACE) in diabetes mellitus (DM) patients with peripheral arterial disease (PAD). A total of 246 DM patients with diagnosed PAD were enrolled in this study.
Amaraporn Rerkasem, Ampica Mangklabruks, Supawan Buranapin, Kiran Sony, Nimit Inpankaew, Rath Rerkasem, Sasinat Pongtam, Kochaphan Phirom, Kitttipan Rerkasem   +8 more
openaire   +2 more sources

TICAGRELOR AND MAJOR ADVERSE LIMB EVENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Journal of the American College of Cardiology, 2020
More potent anti-thrombotic strategies have been shown to reduce major adverse limb events (MALE) in patients with atherosclerosis. Ticagrelor is a potent P2Y12 inhibitor that reduces major adverse cardiovascular events (MACE) in stable patients with prior myocardial infarction and in those ...
Marc P. Bonaca, Deepak Bhatt, Philippe Gabriel Steg, Thomas Zelniker, Warren Cappell, William R. Hiatt, Connie Hess, Marc Sabatine   +7 more
openaire   +1 more source

Association of Anticoagulation and Major Adverse Limb Events After Index Peripheral Endovascular Intervention

The American Journal of Cardiology, 2023
Dual-antiplatelet therapy is commonly prescribed after endovascular intervention for peripheral artery disease. However, it is not known whether therapeutic anticoagulation affects outcomes after peripheral endovascular intervention. We sought to investigate whether therapeutic anticoagulation after peripheral endovascular intervention is associated ...
Niveditta Ramkumar, Philip P. Goodney, Mark A. Creager, Stanislav Henkin   +3 more
openaire   +2 more sources